This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CP-4055, elacytarabine
Description: CP-4055 is a novel cytotoxic drug based on Clavis' proprietary Lipid Vector Technology. The Lipid Vector Technology involves the chemical binding of specific fatty acids (Lipid Vector) to pharmaceutical agents. The resulting analogues are new molecular entities (NME) protected by patents.
CP-4055 is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine [1-ß-D-Arabinofuranosylcytosine (Ara-C] is a potent antineoplastic drug that has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. CP-4055 is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.
Deal Structure: Clavis originally partnered with Ben Venue Laboratories for the manufacturing of elacytarabine.
In 2011, Clavis Pharma signed an agreement with Baxter as a second contract manufacturer for elacytarabine, with the intent to transfer manufacturing in the first quarter 2012.
In October 2013, Clavis Pharma ASA will change their company name to Aqualis ASA.
Pink Sheet Chart: Weekly Trademark Review
Additional information available to subscribers only: